- Home
- MMV vs VRAX Comparison
MMV vs VRAX Comparison
Compare MMV & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- VRAX
- Stock Information
- Founded
- MMV 2015
- VRAX 2013
- Country
- MMV China
- VRAX United Kingdom
- Employees
- MMV N/A
- VRAX N/A
- Industry
- MMV Blank Checks
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MMV Finance
- VRAX Health Care
- Exchange
- MMV Nasdaq
- VRAX Nasdaq
- Market Cap
- MMV 18.8M
- VRAX 17.2M
- IPO Year
- MMV N/A
- VRAX 2022
- Fundamental
- Price
- MMV $0.49
- VRAX $2.80
- Analyst Decision
- MMV
- VRAX
- Analyst Count
- MMV 0
- VRAX 0
- Target Price
- MMV N/A
- VRAX N/A
- AVG Volume (30 Days)
- MMV 149.6K
- VRAX 13.0M
- Earning Date
- MMV 01-01-0001
- VRAX 11-06-2024
- Dividend Yield
- MMV N/A
- VRAX N/A
- EPS Growth
- MMV N/A
- VRAX N/A
- EPS
- MMV N/A
- VRAX N/A
- Revenue
- MMV $9,008,244.00
- VRAX $156,419.00
- Revenue This Year
- MMV N/A
- VRAX $5,169.18
- Revenue Next Year
- MMV N/A
- VRAX $66.97
- P/E Ratio
- MMV N/A
- VRAX N/A
- Revenue Growth
- MMV N/A
- VRAX 1727.11
- 52 Week Low
- MMV $0.41
- VRAX $0.60
- 52 Week High
- MMV $2.05
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- MMV 38.30
- VRAX 46.62
- Support Level
- MMV $0.46
- VRAX $2.40
- Resistance Level
- MMV $0.54
- VRAX $3.26
- Average True Range (ATR)
- MMV 0.05
- VRAX 0.75
- MACD
- MMV -0.00
- VRAX -0.31
- Stochastic Oscillator
- MMV 31.94
- VRAX 9.18
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.